50 results found.

Pediatric Crohn's Disease Clinical Trial using TA-650

Mitsubishi Tanabe Pharma Corporation - Recruiting 6 years to 17 years.
- Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of TA-650 in Pediatric Patients With Moderate to Severe Crohn's Disease.
TA-650

Crohn Disease Clinical Trial using BI 655066 (high dose); BI 655066 (low dose); BI 655066 one dose; placebo dose

Boehringer Ingelheim - Recruiting 18 years to 75 years.
- A Phase II, Multicenter, Randomized, Double-blind, Multiple Dose, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of BI 655066, an IL-23 p19 Antagonist Monoclonal Antibody, in Patients With Moderately to Severely Active Crohn's Disease, Who Are na‹ve to, or Were Previously Treated With Anti-TNF Therapy..
BI 655066 (high dose); BI 655066 (low dose); BI 655066 one dose; placebo dose

Crohn's Disease Clinical Trial using AMG 139

Amgen - Recruiting 18 years to 55 years.
- A Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Mild to Severe Crohn's Disease.
AMG 139

Crohn Disease, or Ulcerative Colitis Clinical Trial using VSL#3

Charles University, Czech Republic - Recruiting N/A or older.
- The Effect of VSL#3 Probiotic Preparation on the Bile Acid Metabolism in Patients With Inflammatory Bowel Disease.
VSL#3

Hepatosplenic T-Cell Lymphoma Clinical Trial using Collection of samples

Janssen Scientific Affairs, LLC - Recruiting N/A or older.
- A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL).
Collection of samples

Crohn's Disease Clinical Trial using GLPG0634; Placebo

Galapagos NV - Recruiting 18 years to 75 years.
- Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration.
GLPG0634; Placebo

Crohn's Disease, Inflammatory Bowel Disease, IBD, or Colitis Clinical Trial using Group 3: ustekinumab approximately 6 mg/kg; Group 1: Placebo; Group 2 ustekinumab 130 mg

Janssen Research & Development, LLC - Recruiting 18 years or older.
- A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2).
Group 3: ustekinumab approximately 6 mg/kg; Group 1: Placebo; Group 2 ustekinumab 130 mg

Inflammatory Bowel Disease, Crohn's Disease, or Ulcerative Coliti Clinical Trial using Infliximab, adalimumab, certolizumab pegol

Oslo University Hospital - Recruiting 18 years or older.
- Anti-TNF-alpha Trough Level Measurements in Inflammatory Bowel Disease.
Infliximab, adalimumab, certolizumab pegol

Crohns Disease Clinical Trial using PDA001; Vehicle Controlled Placebo

Celgene Corporation - Recruiting 18 years to 75 years.
- A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease.
PDA001; Vehicle Controlled Placebo

Crohn's Disease Clinical Trial using Hematopoietic stem cell transplantation

University of California, Los Angeles - Recruiting 18 years to 70 years.
- Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment.
Hematopoietic stem cell transplantation

Crohn's Disease Clinical Trial using PF-00547659 SC injection

Pfizer - Recruiting 18 years to 75 years.
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-00547659 In Subjects With Crohn's Disease.
PF-00547659 SC injection

Crohn's Disease Clinical Trial using AMG 181; Placebo

Amgen - Recruiting 18 years to 65 years.
- A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects With Moderate to Severe Crohn's Disease.
AMG 181; Placebo

Perianal Crohn's Disease Clinical Trial using MSC-AFP

Mayo Clinic - Recruiting 18 years to 65 years.
- A Phase 1 Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Fistulizing Crohn's Disease..
MSC-AFP

Crohn's Disease Clinical Trial using Adalimumab; placebo

Fundacion Clinic per a la Recerca Biom‚dica - Recruiting 18 years or older.
- A Randomized, Double-blinded, Placebo-controlled Study on the Effects of Adalimumab Intralesional Intestinal Strictures of Crohn's Disease Patients.
Adalimumab; placebo

Crohn's Disease, Ileitis, Ileo-colonic and Colonic Crohn's Diseas Clinical Trial using lumbar puncture

Pfizer - Recruiting 18 years to 75 years.
- A Multi Center, Phase 1, Open Label Evaluation Of The Effect Of PF-00547659 (Anti Madcam Monoclonal Antibody) On Cerebrospinal Fluid (CSF) Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Are Anti- TNF Inadequate Responders (TOSCA).
lumbar puncture

Crohn's Disease, or Rheumatoid Arthritis Clinical Trial

University of California, San Diego - Recruiting N/A or older.
- Cimzia (Certolizumab Pegol) Pregnancy Exposure Registry: OTIS Autoimmune Diseases in Pregnancy Project.

Crohn's Disease Clinical Trial using RHB-104; Placebo

RedHill Biopharma Limited - Recruiting 18 years to 65 years.
- A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease.
RHB-104; Placebo

Crohn's Disease Clinical Trial using PF-04236921 SC injection

Pfizer - Recruiting 18 years to 75 years.
- A Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study To Evaluate The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Are Anti-TNF Inadequate Responders (ANDANTE).
PF-04236921 SC injection

Crohn's Disease Clinical Trial

AbbVie - Recruiting 18 years to 65 years.
- Improvement of Work Productivity and Quality of Life With Anti-TNF Therapies Used in Crohn's Disease in Routine Clinical Practice in Turkey.

Crohn's Disease Clinical Trial using Entocort

AstraZeneca - Recruiting 5 years to 17 years.
- A Multicenter, Open Label, Non-comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive.
Entocort

Crohn Disease Clinical Trial using Infliximab

Hvidovre University Hospital - Recruiting 18 years or older.
- The Effect of Infliximab Therapy in Crohn Patients on Regulatory T-cells.
Infliximab

Crohn Disease Clinical Trial using Infliximab

Merck Sharp & Dohme Corp. - Recruiting 18 years to 55 years.
- An Open Label Study to Discover Biomarkers of Intestinal Mucosal Healing in Crohn's Disease (CD).
Infliximab

Crohn's Disease Clinical Trial using Allogeneic Stem Cell Therapy

Northwestern University - Recruiting 18 years to 45 years.
- Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Refractory Crohn's Disease.
Allogeneic Stem Cell Therapy

Crohn's Disease, Inflammatory Bowel Disease, or Ulcerative Coliti Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 8 years to 75 years.
- Study of the Immune Regulation of Idiopathic Inflammatory Bowel Diseases: Crohn's Disease, Ulcerative Colitis, and Other Inflammatory Conditions of the Gut.

Inflammatory Bowel Diseases, Crohn's Disease, Gastrointestinal Di Clinical Trial using Mesalazine, Tripterygium glycosides

Jinling Hospital, China - Recruiting 18 years to 75 years.
- Prospective Experimental of Tripterygium Glycoside in the Treatment of Crohn's Disease for Induction Remission.
Mesalazine, Tripterygium glycosides

Crohn's Disease Clinical Trial using vagus nerve stimulation (VNS)

University Hospital, Grenoble - Recruiting 18 years to 65 years.
- The Anti-inflammatory Effect of Vagus Nerve Stimulation (VNS): a New Approach in the Treatment of Crohn's Disease.
vagus nerve stimulation (VNS)

Crohn's Disease Clinical Trial using MEDI2070; placebo

AstraZeneca - Recruiting 18 years to 65 years.
- A Phase 2a Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects With Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy.
MEDI2070; placebo

Crohn's Disease, or Fistula Clinical Trial using Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.; Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.

Leiden University Medical Center - Recruiting 18 years or older.
- Allogeneic Bone Marrow Derived Mesenchymal Stem Cells for the Treatment of Fistulas in Patients With Refractory Perianal Crohn's Disease.
Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.; Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.

Active Crohn Disease With Terminal Ileal Disease Clinical Trial using Capsule endoscopy and Ileocolonoscopy tests

Given Imaging Ltd. - Recruiting 2 years to 75 years.
- Monitoring Disease Activity Using Video Capsule Endoscopy (VCE) in Crohn's Disease (CD) Subjects Receiving an Immunomodulator (IMM) andor a Biological Treatment.
Capsule endoscopy and Ileocolonoscopy tests

Crohn's Disease Clinical Trial using Adalimumab

AbbVie - Recruiting 18 years to 70 years.
- A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Two Adalimumab Dosing Regimens in Chinese Subjects With Moderately to Severely Active Crohn's Disease and Elevated High-Sensitivity C-reactive Protein.
Adalimumab

Crohn's Disease Clinical Trial using E6011 2 mg/kg; E6011 5 mg/kg; E6011 10 mg/kg

Eisai Inc. - Recruiting 20 years to 64 years.
- A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease.
E6011 2 mg/kg; E6011 5 mg/kg; E6011 10 mg/kg

Crohn's Disease Clinical Trial using adult human mesenchymal stem cells

Osiris Therapeutics - Recruiting 18 years to 70 years.
- A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMALr (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease.
adult human mesenchymal stem cells

Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Clinical Trial using Blood draw from mother; Blood draw from infant; Blood draw from umbilical cord; Certolizumab Pegol

UCB, Inc. - Recruiting 18 years or older.
- A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimziar (Certolizumab Pegol) Phase 1b (Clinical Pharmacology).
Blood draw from mother; Blood draw from infant; Blood draw from umbilical cord; Certolizumab Pegol

Crohn's Disease Clinical Trial using PF-00547659

Pfizer - Recruiting 18 years to 76 years.
- A Multicenter Open-Label Extension Study To Assess Long-Term Safety Of PF-00547659 In Subjects With Crohn's Disease (OPERA II).
PF-00547659

Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, or In Clinical Trial using Anti TNF therapy including infliximab; No Biologics

Janssen Biotech, Inc. - Recruiting 1 Month to 17 years.
- A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease.
Anti TNF therapy including infliximab; No Biologics

Rheumatoid Arthritis, or Crohn's Disease Clinical Trial

UCB, Inc. - Recruiting 18 years or older.
- Observational Study to Evaluate the Safety and Effectiveness of Cimzia in Rheumatoid Arthritis and Crohn's Disease Patients When Using a Comprehensive Program of Tuberculosis Screening and Monitoring.

Crohn's Disease Clinical Trial using Cx601; Saline solution

Cellerix - Recruiting 18 years or older.
- A Phase III, Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicentre Study to Assess Efficacy and Safety of Expanded Allogeneic Adipose-derived Stem Cells (eASCs) for the Treatment of Perianal Fistulising Crohn's Disease Over a Period of 24 Weeks and an Extended Follow-up Period up to 52 Weeks..
Cx601; Saline solution

Crohn's Diseases, Inflammatory Bowel Disease, or Gut Bacteria Clinical Trial using FMT; 5-ASA, Prednisone, Azathioprine or Remicade

The Second Hospital of Nanjing Medical University - Recruiting 14 years to 70 years.
- Efficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Crohn's Diseases in Ileum and Colon.
FMT; 5-ASA, Prednisone, Azathioprine or Remicade

Crohn's Disease Clinical Trial

Haukeland University Hospital - Recruiting 18 years or older.
- High Frequency Ultrasound and Contrast Enhanced Ultrasound of Patients Treated for Deterioration of Crohn's Disease.

Crohn's Disease Clinical Trial using Fecal Microbial Transplantation

Beth Israel Deaconess Medical Center - Recruiting 18 years or older.
- .
Fecal Microbial Transplantation

Crohn's Disease Clinical Trial using Elimination Diet; Dietary Guidelines for Americans

Johns Hopkins University - Recruiting 18 years to 75 years.
- The Relationship of a 'Crohn's Disease Diet' in Reducing Symptoms of Crohn's Disease, Improving Quality of Life, and Decreasing Related Health Care Costs..
Elimination Diet; Dietary Guidelines for Americans

Crohn's Disease, or Perianal Fistulas Clinical Trial using Hyperbaric oxygen

Assaf-Harofeh Medical Center - Recruiting 18 years to 70 years.
- Prospective Open-label Study of the Efficacy of the Addition of Hyperbaric Oxygen to the Treatment of Patients With Perianal Fistulas Already Treated With TNF Alpha Blockers.
Hyperbaric oxygen

Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, or In Clinical Trial using Blood and stool sample

Boston Medical Center - Recruiting 18 years or older.
- Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients.
Blood and stool sample

Crohn's Disease, Ulcerative Colitis, or Inflammatory Bowel Diseas Clinical Trial

Medical College of Wisconsin - Recruiting N/A to 18 years.
- Genetic Markers as Predictors of Phenotypes in Pediatric Onset Crohn's Disease.

Iron Deficiency Anaemia, Inflammatory Bowel Disease, or Crohn's D Clinical Trial using ST10-021; Placebo Comparator

Iron Therapeutics - Recruiting 18 years or older.
- A Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study With Oral ST10-021 for the Treatment of Iron Deficiency Anaemia in Subjects With Quiescent Crohn's Disease Where Oral Ferrous Preparations Have Failed or Cannot be Used (AEGIS 2).
ST10-021; Placebo Comparator

Crohn's Disease, or Ulcerative Colitis Clinical Trial using smoking of cannabis; smoking cigarettes with placebo

Meir Medical Center - Recruiting 20 years to 70 years.
- A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease.
smoking of cannabis; smoking cigarettes with placebo

Crohn's Disease Clinical Trial using Pravastatin

University of Virginia - Recruiting 18 years to 65 years.
- Pravastatin Therapy in Patients With Active Crohn's Disease: A Pilot Study.
Pravastatin

Complicated Crohn's Disease Clinical Trial

Tel-Aviv Sourasky Medical Center - Recruiting 18 years or older.
- Use of Fecal Calprotectin as a Surrogate Marker for Macroscopic Recurrence of Disease in Patients With Crohn's Disease After Intestinal Resection.

Inflammatory Bowel Disease, Ulcerative Colitis, or Crohn's Diseas Clinical Trial

Children's Hospital Boston - Recruiting N/A to 18 years.
- Phase I Evaluation of Urinary Isoprostane Levels in Pediatric Patients With Inflammatory and Non-Inflammatory Gastrointestinal Disease.